Navigation Links
Low dose of targeted drug might improve cancer-killing virus therapy
Date:6/16/2014

COLUMBUS, Ohio Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

Viruses that are designed to kill cancer cells oncolytic viruses have shown promise in clinical trials for the treatment of brain cancer and other solid tumors. This cell and animal study suggests that combining low doses of the drug bortezomib with a particular oncolytic virus might significantly improve the ability of the virus to kill cancer cells during oncolytic virus therapy.

The research is published in the journal Clinical Cancer Research.

"These findings pave the way for a treatment strategy for cancer that combines low doses of bortezomib with an oncolytic virus to maximize the efficacy of the virus with little added toxicity," says principal investigator Balveen Kaur, PhD, professor and vice chair of research, Department of Neurological Surgery and Radiation Oncology, and a member of the OSUCCC James Translational Therapeutics Program.

"Because bortezomib is already approved by the Food and Drug Administration, a clinical trial could be done relatively quickly to test the effectiveness of the drug-virus combination," Kaur says.

Bortezomib inhibits the activity of proteasomes, structures in cells that break down and recycle proteins. Kaur notes that blocking these "cellular recycling plants" activates a cellular stress response and increases the expression of heat shock proteins. This reaction, which can lead to bortezomib resistance, makes the cells more sensitive to oncolytic virus therapy with little additional toxicity.

For this study, Kaur and her colleagues used a herpes simplex virus-type 1 oncolytic virus. Key technical findings include:
'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. New research could provide key to overcoming resistance to HER2 targeted cancer treatments
2. New Penn-designed gel allows for targeted therapy after heart attack
3. Cancer therapy may be too targeted
4. Researchers develop antibody-targeted treatment for recurrent small-cell lung cancer
5. Scientists uncover image of muscular dystrophy defect & design targeted drug candidates
6. Targeted synthesis of natural products with light
7. Targeted treatment can significantly reduce relapse in children with AML leukemia
8. Fruit pest targeted by genomic research
9. Researchers use nanoscale patches to sensitize targeted cell receptors
10. Targeted culling of deer controls disease with little effect on hunting
11. With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... March 17, 2015  MecklerMedia Corporation (OTCQX: MECK) ... for service robots ever held in ... on May 11-13, 2015 at the Javits Convention ... the event include: Acorn Product Development; Axis NJ; ... Kinova Robotics; Littler; NewBotic Corporation; Neya Systems LLC; ...
(Date:3/12/2015)... 2015 Beta Systems today ... access management (IAM) solution for a fixed price ... System,s new IAM package, customers benefit from the ... multiple IAM implementations across different industries. The new ... as any necessary services and consulting. It spans ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... a cellular trigger that normally regulates replenishment of ... in mice. Removing the abnormal stimulation causes the ... a possible treatment for the lethal, aggressive brain ... Erica L. Jackson, of the University of California, ...
... published by BioMed Central, the open access publisher, received ... in the top 10 of their 2005 Journal Citation ... Factor exceeding 3.00, open access journals are confirmed as ... Central's flagship title covering biology in the post-genomic era, ...
... scientists working at the epicenter of the AIDS epidemic ... virus (HIV) "exhausts" killer T cells that would otherwise ... simply "turn off" fully functional T cells by flipping ... studies, however, the scientists showed that they could reinvigorate ...
Cached Biology News:Possible birthplace of malignant brain tumors identified 2Impressive new Impact Factors for BioMed Central's open-access journals 2How HIV 'exhausts' killer T cells 2How HIV 'exhausts' killer T cells 3How HIV 'exhausts' killer T cells 4
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, will ... Align Technology, on “ Conducting Postmarket Registries - Rationale ... Conference and Exhibition on April 25th through April 28th ... poster presentation, Ale Gicqueau and Victor Chen will discuss ... the requirements and resources to conduct the registry, as ...
(Date:3/25/2015)... , March 25, 2015 Optimal Research, ... Vaccine Industry Excellence (ViE) Award "Best Clinical Site or ... year that Optimal has been selected as a nominee ... Congress, receiving a "Highly Recommended" distinction in 2014. The ... of the efforts, accomplishments, and positive contributions of companies ...
(Date:3/25/2015)... , CAMBRIDGE, Mass. and ... NextCODE, which provides comprehensive capabilities for using the genome to ... on their publication of the largest studies of whole-genome data ... online in Nature Genetics – are ... sequence variation, authored by a team of deCODE scientists led ...
(Date:3/25/2015)... MN (PRWEB) March 25, 2015 ... breakthrough in nanoparticle technology that will enable broader ... many other diseases with a simple breath screen. ... on the U.S. Food and Drug Administration (FDA) ... launch of the innovative Nanoparticle Biomarker Tagging device. ...
Breaking Biology Technology:Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 2Ancon Medical Researchers Make Nanotechnology Breakthrough for Disease Screening Technology 3
... to Include Screening for Targeted Cancer Drugs ... Human Disease Models -, HOPKINTON, Mass., April ... CALP ) today announced a partnership with Horizon,Discovery ... and,Services, (CDAS) oncology cell line and screening capabilities ...
... ADVENTRX,Pharmaceuticals, Inc. (Amex: ANX ) announced today ... position of vice president of manufacturing.,Mr. Hechavarria will ... operations., "We are pleased to have recruited ... chief executive officer. "He brings experience and,leadership in ...
... includes upfront, milestone and royalty payments on future ... ... 8 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc.,("Lorus") (TSX: LOR; AMEX: LRP), a ... technologies,for the management of cancer, announced today that its subsidiary GeneSense,Technologies, ...
Cached Biology Technology:Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines 2Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines 3ADVENTRX Appoints Vice President of Manufacturing 2ADVENTRX Appoints Vice President of Manufacturing 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 5
...
... MS/MS analysis & visualization ... across multiple samples. Combine ... for increased confidence. Get ... information from your MS/MS ...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Biology Products: